David Liljenquist, MD
Basic profileRocky Mountain Diabetes and Osteoporosis Center
David Liljenquist is an Endocrinology/Metabolic physician affiliated with Rocky Mountain Diabetes and Osteoporosis Center. OpenAlex indexes 51 publications with 4,219 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3910 Washington Parkway
Idaho Falls, ID 834047596
Telephone
208-523-1122Provider last certified this registry record 21 Sept 2021.
Clinical trials
- Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®
Sponsor: Medtronic MiniMed, Inc.
- Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems
Sponsor: Abbott Diabetes Care
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20256 payments
- Chiesi USA, Inc.Program year20253 payments
- Madrigal PharmaceuticalsProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
41.9%Insulin Analog11.6%Lantus Solostar21%Tresiba Flextouch U-10013%Novolog Flexpen8%Toujeo Solostar7%Tresiba Flextouch U-2006%Humalog Kwikpen U-1006%Insulin Lispro Kwikpen U-1006%Novolog5%Basaglar Kwikpen U-1004%Fiasp Flextouch4%Humalog3%Lantus3%Insulin Aspart Flexpen3%Levemir Flexpen2%Insulin Lispro2%Toujeo Max Solostar2%Humalog Kwikpen U-2001%Admelog1%Lyumjev Kwikpen U-1001%Admelog Solostar1%Soliqua 100-331%Insulin Aspart1%Fiasp1%Xultophy 100-3.61%Part D<11 patientsBiguanide (metformin)8.2%Metformin Hcl Er79%Metformin Hcl21%Part D≥389 patients+ 17 more classes in this area
Cardiovascular
28.8%Statin10.8%Atorvastatin Calcium43%Rosuvastatin Calcium33%Simvastatin19%Pravastatin Sodium5%Lovastatin1%Part D<11 patientsAngiotensin receptor blocker (ARB)4.9%Losartan Potassium66%Losartan-Hydrochlorothiazide11%Irbesartan7%Valsartan5%Irbesartan-Hydrochlorothiazide4%Valsartan-Hydrochlorothiazide3%Olmesartan Medoxomil3%Olmesartan-Hydrochlorothiazide1%Part D<11 patients+ 16 more classes in this area
Hormonal (systemic)
10.8%l-Thyroxine9.2%Levothyroxine Sodium92%Synthroid8%Part D≥451 patientsl-Triiodothyronine0.6%Liothyronine Sodium100%Part D≥34 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes
Diabetes Technology & Therapeutics
2026 - A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
New England Journal of Medicine
2025 - Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design
Journal of Diabetes Science and Technology
2025 - Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study
Diabetes Technology & Therapeutics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”